TRANSGENE BIOTEK LTD.

Transgene Biotek Ltd announced its Unaudited Standalone and Consolidated Financial Results for the quarter and half-year ended September 30, 2026. The Board of Directors also approved the Notice for the 36th Annual General Meeting (AGM) scheduled for December 30, 2026, and the Directors' Report for FY 2025-26. The company also approved the re-appointment of Dr. K. Koteswara Rao as Chairman and Managing Director for a further period of one year, subject to shareholder approval. The Register of Members and Share Transfer Books will be closed from December 24 to December 30, 2026, for the AGM.

Transgene Biotek Ltd announced that its Board of Directors, in a meeting held on November 13, 2026, approved the unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. The board also took on record the limited review reports for these results. Additionally, the company approved the notice for its 36th Annual General Meeting (AGM) for FY 2025-26, scheduled for December 30, 2026. The Directors' Report for FY 2025-26 was also approved. The register of members and share transfer books will be closed from December 24 to December 30, 2026. Mrs. Geeta Servani was appointed as the scrutinizer for the e-voting process. The re-appointment of Dr. K. Koteswara Rao as Chairman and Managing Director for one year was approved, subject to shareholder approval.

Transgene Biotek Ltd has announced a Board of Directors meeting scheduled for November 13, 2026. The meeting will primarily focus on approving the Un-Audited Financial Results (Standalone & Consolidated) for the quarter and half-yearly ended September 30, 2026, along with the Limited Review Report. Additionally, the board will consider and approve the Notice and Board's Report for the 36th Annual General Meeting (AGM) for FY 2025-26, including setting the Record Date, Book Closure period, and e-voting dates. The re-appointment of Dr. K. Koteswara Rao as Chairman & Managing Director for a further one-year term will also be discussed, subject to shareholder approval. The trading window for securities remains closed until 48 hours after the financial results are published.

Transgene Biotek Limited's Board of Directors accepted the resignation of M/s. Harish Gummadi & Co., Chartered Accountants, as Statutory Auditors, effective November 3, 2026. The resignation was due to unforeseen circumstances and a medical emergency affecting their professional availability for the Q2 FY27 limited review. The Board, on the Audit Committee's recommendation, appointed M/s. Ranganath Prasad & Co. as the new Statutory Auditors to fill the casual vacancy. This appointment is subject to shareholder approval at the upcoming general meeting and will last until the conclusion of the next Annual General Meeting.

Transgene Biotek Ltd announced the resignation of its statutory auditors, M/s. Harish Gummadi & Co., Chartered Accountants, effective November 3, 2026. The auditors cited "unforeseen circumstances" preventing them from devoting sufficient time to the company's affairs, impacting their ability to complete the limited review for the quarter ended September 30, 2026, within the prescribed timeline. The company will initiate the process to appoint a new statutory auditor in compliance with relevant regulations.

Transgene Biotek Limited's Board of Directors has approved the appointment of M/s. Harish Gummadi & Co., Chartered Accountants, as the new Statutory Auditors. This appointment fills a casual vacancy caused by the resignation of the previous auditors, M/s. Eswara Rao & Co. The appointment is subject to shareholder approval at a general meeting and the new auditors will serve until the conclusion of the next Annual General Meeting. The Board also noted the resignation details and confirmations from the newly appointed firm.

Transgene Biotek Ltd has submitted additional details to BSE regarding the resignation of its statutory auditors, M/s. Eswara Rao & Co., Chartered Accountants. The auditors cited "unforeseen circumstances" as the reason for their resignation, which became effective on October 28, 2026. They were appointed on October 10, 2026, to fill a casual vacancy. The auditors confirmed they had not commenced audit work and had no concerns regarding management cooperation. The company is complying with SEBI disclosure requirements.

Transgene Biotek Ltd has submitted additional details to BSE Limited regarding the resignation of its statutory auditors, M/s Vasavi & Co., Chartered Accountants. The auditors cited pre-occupation with other assignments as the reason for their resignation, stating they are unable to devote sufficient time to the company's affairs. This submission follows an observation from BSE and provides the required clarifications under SEBI (LODR) Regulations, 2015. The auditors' appointment was effective from December 30, 2023, and was scheduled to expire on September 30, 2028. The company has requested that the revised corporate announcement and additional details be taken on record.

Transgene Biotek Ltd has submitted additional details to BSE Limited regarding the resignation of its statutory auditor, M/s. Eswara Rao & Co., Chartered Accountants. The auditors cited pre-occupation with other assignments and insufficient time as the reason for their resignation, effective October 28, 2026. They confirmed no audit work had commenced and no impediments were faced during their brief tenure. The company is complying with SEBI (LODR) Regulations, 2015, and the Companies Act, 2013, for this disclosure.

Transgene Biotek Ltd has announced the resignation of its statutory auditors, M/s. Eswara Rao & Co., Chartered Accountants. The auditors cited "pre-occupation in other assignments" as the reason for their resignation, stating they are unable to devote sufficient time to the company's affairs. The resignation is effective immediately as of October 28, 2026. The company plans to appoint a new statutory auditor in compliance with the Companies Act, 2013, and SEBI LODR Regulations. This marks the second auditor resignation for the company within a short period, following the earlier resignation of M/s. Vasavi & Co.